Filip K. Knop retweeted
GIP did not prevent #hypoglycaemia following excess prandial insulin and physical activity after meal ingestion in males with type 1 #diabetes #T1D dom-pubs.pericles-prod.liter…
Filip K. Knop retweeted
🧠Meet Dr. Liva Krogh (@Metabolcenter), co-investigator & grant recipient of the #EFSD/ @novonordisk A/S Programme for #Diabetes Research in 🇪🇺.
Their project investigated how the incretin hormones GIP & GLP-1 act on tissues outside the pancreas.
More 👉 europeandiabetesfoundation.o…

ALT Graphic titled ‘Recipient Research Portrait’ featuring Doctor Liva Sophie Lavlund Krogh from the Center for Clinical Metabolic Research, Gentofte Hospital. The design includes a portrait photo of her smiling, along with EFSD, European Foundation for the Study of Diabetes, branding.

ALT Graphic titled ‘Separate and combined extrapancreatic effects of the incretin hormones.’ Text explains that Liva Sophie Lavlund Krogh investigates the extrapancreatic effects of the incretin hormones GIP and GLP-1 in totally pancreatectomized patients, showing their impact on various tissues independent of pancreatic insulin and glucagon. EFSD logo included.
Filip K. Knop retweeted
Don't throw away those sneakers just yet #Exercise cell.com/trends/endocrinolog…
Today, @HannahVigh et al. unleash a freely available and searchable database of the human intestinal transcriptome - an atlas of the expression of 19,739 genes from 16 sites along the intestinal tract. Check out the landscape of your favourite gene here: rnaseq.gubra.dk
Filip K. Knop retweeted
When you eat, for how long vs. how much. The pursuit for differentiated outcomes continues medrxiv.org/content/10.1101/…
Filip K. Knop retweeted
🌍 For Half of Humanity: Why we need action on obesity
Obesity is one of the defining global health and equity challenges of our time. Today, over 1 billion people live with obesity, and without bold action, 4 billion - half of the world’s population - will be affected by overweight or obesity by 2035.
This campaign is our urgent call to action in the lead-up to the 2025 UN High-Level Meeting on Non-Communicable Diseases (HLM on NCDs). Our goal is clear: to secure global recognition of obesity as a chronic disease, drive equitable access to care, and catalyse multisectoral solutions.
Obesity doesn’t just impact individuals - it fuels a wider crisis of non-communicable diseases including diabetes, heart disease and cancer. And it’s not just a high-income country issue - 88% of future obesity cases will occur in low- and middle-income countries.
But we have the tools to act: proven public health policies, emerging treatments, and growing political momentum. The HLM must our moment to demand action.
Join us in demanding:
✅ Obesity recognised as a disease in the HLM Political Declaration
✅ Commitment to WHO recommendations & Acceleration Plan
✅ People with lived experience at the heart of global solutions
🌐 Visit our website to explore campaign materials, take action, and learn why this moment matters. We have #4BillionReasons to act.
🔗 worldobesity.org/HLM4
#4BillionReasons #HalfOfHumanity
Filip K. Knop retweeted
Here the authors propose that gut #microbiota derived peptides exhibit potential for prevention and treatment of human metabolic disorders nature.com/articles/s41564-0…
Filip K. Knop retweeted
And you thought #metformin lowered glucose via the liver? Here loss-of-function and gain-of-function studies suggest that VMH Rap1 is indispensable for the antidiabetic effects of metformin in mice #diabetes science.org/doi/10.1126/scia…
Filip K. Knop retweeted
A new comprehensive review of the proglucagon-derived peptides #disbetes #obesity #shortbowelsyndrome journals.physiology.org/doi/…
Filip K. Knop retweeted
Adult & Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study
➡️Still more to learn on trajectories of single antibody positivity… however stage 2 T1D and progression more defined in adults or children
diabetesjournals.org/care/ar…
Filip K. Knop retweeted
A 7 day treatment period in humans with type 1 diabetes shows dapagliflozin increases plasma ketone concentrations without affecting the secretion of GLP-1, glucagon or somatostatin. link.springer.com/article/10… @DiabetologiaJnl
Filip K. Knop retweeted
Roles for VAMP-8 in GLP-1R recycling in beta cells diabetesjournals.org/diabete…
Filip K. Knop retweeted
Studies in mice reveal that LEAP2 analogs have the potential to enhance the efficacy of glucagon-like peptide 1 receptor agonism and support durable #weightloss diabetesjournals.org/diabete…
Filip K. Knop retweeted
Filip K. Knop retweeted
The Banting Award for scientific achievement to Professor Steven Kahn. A stellar career with scientific leadership across multiple domains #diabetes A poignant celebration unfolds #ADA2025 @AmDiabetesAssn
Filip K. Knop retweeted
The vehicle associated phosphoprotein REPS1 identified as a convergence point for #insulin and #exercise signaling, presenting a potential therapeutic target for treating individuals with #insulin resistance @CellRepMed cell.com/cell-reports-medici…
Filip K. Knop retweeted
GDF15 is still a mystery hormone: Trends in Endocrinology & Metabolism
Now finally out in print!
cell.com/trends/endocrinolog…
Filip K. Knop retweeted
Go with the flow-endogenous GIP and splanchnic blood flow in humans diabetesjournals.org/diabete…
Filip K. Knop retweeted
MARCH2, an E3 ubiquitin ligase, safeguards against metabolic dysfunction-associated #fattyliver disease.
By promoting FASN degradation, MARCH2 reduces #hepatic #lipogenesis and steatosis, highlighting a potential therapeutic avenue for #MAFLD.
🔗sciencedirect.com/science/ar…


















